The rapid pace of medical innovation continues to redefine healthcare. In 2024, remarkable breakthroughs—from cancer therapies to treatments for rare diseases—have not only improved lives but also shaped the future of medicine.
Advancements in Cancer Treatment
Enhertu Broadens Scope
Enhertu, an antibody-drug conjugate, now treats breast cancers with lower HER2 levels, combining targeted therapy with chemotherapy for precision care.
Tagrisso’s Early Promise
Tagrisso, already a mainstay for advanced lung cancer, shows potential in preventing recurrence in earlier stages, marking another step forward in cancer prevention.
GLP-1 Medications Beyond Diabetes
GLP-1 drugs, like semaglutide and tirzepatide, have expanded beyond diabetes and weight loss. Semaglutide reduces heart attack and stroke risks, while tirzepatide is the first approved treatment for sleep apnea. Ongoing efforts to develop oral versions promise broader accessibility.
HIV Prevention Breakthrough: Lenacapavir
Gilead’s long-acting injectable, lenacapavir, proved 100% effective in preventing HIV in a large clinical trial. Its twice-yearly dosing offers a major advancement, though global access challenges persist.
Precision Medicine Milestones
- Duvyzat: A nonsteroidal treatment for all genetic types of Duchenne muscular dystrophy.
- Cobenfy: A groundbreaking schizophrenia drug targeting cholinergic receptors.
- Winrevair: The first drug to address pulmonary arterial hypertension at its root cause.
Future Frontiers
From CAR-T therapy for lupus to gene-edited pig organ transplants, 2024 has opened new frontiers. Advances like spinal cord stimulation devices offer renewed hope for mobility.
Check out our AAV CDMO service to expedite your gene therapy research
PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.
Related News
[2025/1/3] Gene and Cell Therapy- weekly digest from PackGene
FeaturedNewsArticlesPackGene's NewsletterReceive the latest news and insights to your inbox.About PackGenePackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span...
Pfizer ends work on Sangamo’s hemophilia gene therapy, crushing biotech’s hopes
Despite reporting a Phase 3 win this summer, Pfizer terminated its hemophilia A gene therapy pact with Sangamo Therapeutics in a move that cast a pall on the California biotech’s future. In response to Monday’s news about giroctocogene fitelparvovec, Sangamo’s shares...
A Look at 2024’s Patent Expirations and Generic Competition
The pharmaceutical industry faced a major shift in 2024 as several blockbuster drugs lost patent protection. This change brought challenges and opportunities for companies and patients. Pharmaceutical firms experienced revenue declines and tougher competition from...
CARsgen Announces Positive Topline Results from China GC/GEJ Pivotal Phase II Clinical Trial of Claudin18.2 CAR-T (Satri-cel)
SHANGHAI, Dec. 30, 2024 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces the positive results from the pivotal...
Related Services
AAV Packaging Services
READ MORE
Off-the-Shelf AAV Products
READ MORE
